The novel modifiers identified in this model system point to potential therapeutic targets that might be more amenable to manipulation than MeCP2, and thus they provide new opportunities to develop therapies for Rett syndrome and related neurological disorders. The gene discussed is MECP2; the disease is atypical Rett syndrome.